Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Kaifeng Qiu"'
Autor:
Jianhong Zhu, Guanghui Chen, Zhichao He, Yayuan Zheng, Siyuan Gao, Jianfang Li, Yin Ling, Xiaoxia Yu, Kaifeng Qiu, Junyan Wu
Publikováno v:
EClinicalMedicine, Vol 37, Iss , Pp 100951- (2021)
Background: The association between immune checkpoint inhibitors (ICIs) and Stevens-Johnsons syndrome (SJS) /toxic epidermal necrolysis (TEN) is unclear. We assessed the risk of SJS and TEN related to ICIs, via a systematic analysis of SJS/TEN cases
Externí odkaz:
https://doaj.org/article/ffc10bbf8de14efe818c01ecf9803249
Autor:
Zhichao He, Kakei Lam, Wenxia Zhao, Shan Yang, Yu Li, Jiayao Mo, Siyuan Gao, Dan Liang, Kaifeng Qiu, Min Huang, Junyan Wu
Publikováno v:
Acta Diabetologica. 60:401-411
To investigate the main feature and the association between euglycemic diabetic ketoacidosis (euDKA) /diabetic ketoacidosis (DKA) and sodium-dependent glucose transporters 2 inhibitors (SGLT-2i) from the FDA adverse event reporting system (FAERS).Cas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c55d6caa60be6562ec0e811810b7fd0a
https://doi.org/10.1007/s00592-022-02015-6
https://doi.org/10.1007/s00592-022-02015-6
Publikováno v:
Immunotherapy. 14:859-869
Renal cell carcinoma (RCC) is a common cancer in the USA. Up to 30% of patients with RCC are in an advanced stage of disease at diagnosis. RCC is difficult to cure, with an 11% chance of survival after 5 years for patients with advanced RCC. A recent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::608074bfbcf61457db5e1877e11e9c6c
https://doi.org/10.2217/imt-2021-0156
https://doi.org/10.2217/imt-2021-0156
Autor:
Siyuan Gao, Zhichao He, Jianhong Zhu, Dan Liang, Wenxia Zhao, Shan Yang, Wei Jiang, Kaifeng Qiu, Xiaoxia Yu, Junyan Wu
Publikováno v:
Pharmacoepidemiology and Drug Safety. 31:1199-1205
Immune checkpoint inhibitors (ICIs) have been widely used in cancer treatment; however, some case reports suggested that ICIs treatment might result in ileus. This study aims to comprehensively reveal the relationship between ileus and ICIs treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a508c1ab92429a3c446d343411bc9588
https://doi.org/10.1002/pds.5493
https://doi.org/10.1002/pds.5493
Autor:
Zepeng Chen, Ming Li, Shuzhen Li, Yuxi Li, Junyan Wu, Kaifeng Qiu, Xiaoxia Yu, Lin Huang, Guanghui Chen
Publikováno v:
Expert opinion on drug safety.
Romosozumab is a novel drug for the treatment of osteoporosis. The adverse reactions of romosozumab still need to be explored. The FDA Adverse Event Reporting System (FAERS) provides an enormous dataset for adverse events (AEs) analysis. AEs register
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3eac20521d3cfe0701c8a43703ddd825
https://pubmed.ncbi.nlm.nih.gov/36178002
https://pubmed.ncbi.nlm.nih.gov/36178002
Autor:
Jianhong Zhu, Dan Liang, Junyan Wu, Zhichao He, Xiaoxia Yu, Qing He, Kaifeng Qiu, Yanping Guan
Publikováno v:
Annals of Palliative Medicine. 10:8651-8664
Background Drug-induced liver injury (DILI) has become one of the most common and serious adverse drug reactions owing to its high morbidity and leading cause of hepatic failures, which had attracted great attentions worldwide in the past two decades
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7d1adbae3690bd255241cdea326d628
https://doi.org/10.21037/apm-21-981
https://doi.org/10.21037/apm-21-981
Autor:
Zhichao He, Jiayao Mo, Wei Jiang, Jianhong Zhu, Shan Yang, Siyuan Gao, Kakei Lam, Yu Li, Kaifeng Qiu, Min Huang, Junyan Wu
Publikováno v:
International Journal of Gynecological Cancer; Aug2023, Vol. 33 Issue 8, p1237-1246, 10p
Autor:
Yin Lin, Jianhong Zhu, Jianfang Li, Yayuan Zheng, Yong Wang, Xiaoxia Yu, Wenxia Zhao, Zhichao He, Junyan Wu, Chuxiong Chen, Kaifeng Qiu
Publikováno v:
The Lancet Diabetes & Endocrinology. 8:192-205
Summary Background Considering the global burden of diabetes and associated cardiovascular disease, an urgent need exists for the best treatment, which should be based on the best available evidence. We examined the association between glucose-loweri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d81513a118d4027f87695cfa9ca01898
https://doi.org/10.1016/s2213-8587(19)30422-x
https://doi.org/10.1016/s2213-8587(19)30422-x
Autor:
Jianhong Zhu, Muhua Luo, Dan Liang, Siyuan Gao, Yayuan Zheng, Zhichao He, Wenxia Zhao, Xiaoxia Yu, Kaifeng Qiu, Junyan Wu
Publikováno v:
International immunopharmacology. 110
To estimate the risk of type 1 diabetes associated with immune checkpoint inhibitor (ICI-T1DM), and to describe its clinical features.ICI-T1DM events in randomized clinical trials (RCTs) available in electronic databases were systematically reviewed.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ccfe7768528abbf8239538d4ec4d9cf
https://pubmed.ncbi.nlm.nih.gov/35978507
https://pubmed.ncbi.nlm.nih.gov/35978507
Publikováno v:
Thorax. 77(7)
We examined case reports of immune checkpoint inhibitors (ICIs) associated pulmonary tuberculosis (PT) using data from the Food and Drug Administration Adverse Event Reporting System database. Disproportionality analysis was performed by using the re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62ea2a607a8f2340f66b8a5107c552a6
https://pubmed.ncbi.nlm.nih.gov/35277447
https://pubmed.ncbi.nlm.nih.gov/35277447